Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson's Disease

被引：16
|
作者：
Gilligan, Paul J. [1 ]
机构：
[1] Penn Drug Discovery Inst, Doylestown, PA 18902 USA
来源：
CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2015年 / 15卷 / 10期
关键词：
Kinase inhibitors; Leucine-rich repeat kinase 2 (LRRK2); Parkinson's disease; ALPHA-SYNUCLEIN; GENE; MUTATIONS; G2019S; POTENT; DISCOVERY; PHOSPHORYLATION; EXPRESSION; FAMILIES; MODEL;
D O I：
10.2174/156802661510150328223655
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) have been linked to several familial and sporadic late-onset cases of Parkinson's disease. The cumulative data for the effects of mutant forms of this enzyme on neuronal degradation and the pathophysiology of Parkinson's disease create a compelling case for drug discovery based on inhibition of the mutant forms of LRRK2. This review focuses on structure-activity relationships for inhibitors of LRRK2 and the data supporting a potential role of these agents in treating Parkinson's disease.
引用
收藏
页码：927 / 938
页数：12
相关论文
共 50 条
  • [41] Targeting leucine-rich repeat kinase 2 in Parkinson's disease
    Chan, Sharon L.
    Angeles, Dario C.
    Tan, Eng-King
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (12) : 1471 - 1482
  • [42] Leucine-rich repeat kinase 2: Relevance to Parkinson's disease
    Guo, Luxuan
    Wang, Wen
    Chen, Shu G.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (09): : 1469 - 1475
  • [43] Hybrid enhanced sampling approaches to gain structural insights into leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease mutation
    Ojha, Anupam A.
    Amaro, Rommie E.
    BIOPHYSICAL JOURNAL, 2023, 122 (03) : 187A - 187A
  • [44] The tale of proteolysis targeting chimeras (PROTACs) for Leucine-Rich Repeat Kinase 2 (LRRK2)
    Konstantinidou, Markella
    Oun, Asmaa
    Pathak, Pragya
    Zhang, Bidong
    Wang, Zefeng
    ter Brake, Frans
    Dolga, Amalia M.
    Kortholt, Arjan
    Domling, Alexander
    CHEMMEDCHEM, 2021, 16 (06) : 959 - 965
  • [45] Identification and Characterization of a Leucine-Rich Repeat Kinase 2 (LRRK2) Consensus Phosphorylation Motif
    Pungaliya, Pooja P.
    Bai, Yuchen
    Lipinski, Kerri
    Anand, Vasanti S.
    Sen, Saurabh
    Brown, Eugene L.
    Bates, Brian
    Reinhart, Peter H.
    West, Andrew B.
    Hirst, Warren D.
    Braithwaite, Steven P.
    PLOS ONE, 2010, 5 (10):
  • [46] Missense mutations in the leucine-rich repeat kinase 2 (LRRK2) gene can cause late-onset Parkinson disease
    Daher, J. P. L.
    BRAIN PATHOLOGY, 2014, 24 : 71 - 72
  • [47] The Role of the Leucine-Rich Repeat Kinase 2 (LRRK2) in Development and Severity of Inflammatory Bowel Disease (IBD)
    Gruber, Sven
    Frey-Wagner, Isabelle
    Wang, Yu
    Cee, Alexandra
    Leonardi, Irina
    Lang, Silvia
    Bettoni, Carla
    Shimshek, Derya R.
    van der Putten, Herman
    Rogler, Gerhard
    Wagner, Carsten A.
    GASTROENTEROLOGY, 2013, 144 (05) : S441 - S441
  • [48] Patient-Control Association Study of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene in South African Parkinson's Disease Patients
    Bardien, Soraya
    Blanckenberg, Janine
    van der Merwe, Lize
    Farrer, Matthew J.
    Ross, Owen A.
    MOVEMENT DISORDERS, 2013, 28 (14) : 2039 - 2040
  • [49] Curcumin exposure induces expression of the Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells
    Ortiz-Ortiz, Miguel A.
    Moran, Jose M.
    Ruiz-Mesa, Luz M.
    Niso-Santano, Mireia
    Bravo-SanPedro, Jose M.
    Gomez-Sanchez, Ruben
    Gonzalez-Polo, Rosa A.
    Fuentes, Jose M.
    NEUROSCIENCE LETTERS, 2010, 468 (02) : 120 - 124
  • [50] LEUCINE-RICH REPEAT KINASE2 (LRRK2) ASSOCIATED PARKINSON'S DISEASE: LESS VULNERABLE DURING COVID-19 PANDEMIC?
    Gharbi, A.
    Kacem, I.
    Sghaier, I.
    Mrabet, S.
    Souissi, A.
    Gargouri, A.
    Nasri, A.
    Gouider, R.
    PARKINSONISM & RELATED DISORDERS, 2023, 113 : 29 - 29
12345